Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Pembrolizumab vs Observation in Stage I NSCLC
NCT04317534Phase 2Recruiting
- Start
- May 2020
- Primary completion
- Apr 2027
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC). Started May 2020; status: recruiting.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04317534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04317534.